RxDoctor Payments Data

Kim Faulkner, MD

Family Medicine · St Petersburg, FLNPI 1952458069

Payments from drug & device makers

$6,465in general payments, 2019–2025

Across 152 payments — averaging $42.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • AbbVie$878
  • Amgen$568
  • GSK$564
  • Abbott$504
  • Dexcom, Inc.$395
  • plus $2K from 14 others

What the payments were for

  • Food & beverage$6,465100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,465 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$305
Medicare patients
12
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol65$81,142
MounjaroTirzepatide36$40,812
OzempicSemaglutide34$39,405
CreonLipase/Protease/Amylase13$19,357
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$19,316
EliquisApixaban12$18,097
JardianceEmpagliflozin12$17,490
JanuviaSitagliptin Phosphate11$16,478
XareltoRivaroxaban14$14,081
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$5,952
Varenicline Tartrate14$4,193
EntrestoSacubitril/Valsartan12$3,929
Famotidine103$2,599
Fluticasone Propionate119$2,425
Gabapentin132$2,102

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$1,937$81,14265 claims
Lilly USA, LLCMounjaro$365$40,81236 claims
Novo NordiskOzempic$266$39,40534 claims
AbbVieCreon$878$19,35713 claims
GSKTrelegy Ellipta$564$19,31627 claims
PfizerEliquis$17$18,09712 claims
MerckJanuvia$128$16,47811 claims
Johnson & JohnsonXarelto$121$14,08114 claims
NovartisEntresto$25$3,92912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →